An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Silverback Therapeutics, Inc. (Nasdaq: SBTX) will participate in the H.C. Wainwright 24th Global Investment Conference from May 23-25, 2022. CEO Laura Shawver, Ph.D., will provide a corporate overview on May 24 at 7:00 AM ET. The presentation will be available for 30 days on their Investor Relations website. Silverback develops therapeutics for chronic viral infections, cancer, and other diseases using its ImmunoTAC technology platform, which targets specific disease sites with monoclonal antibodies.
Positive
None.
Negative
None.
SEATTLE--(BUSINESS WIRE)--
Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today announced that Silverback management will participate in the H.C. Wainwright 24thGlobal Investment Conference from May 23-25, 2022.
Laura Shawver, Ph.D., Silverback’s Chief Executive Officer, will provide a corporate overview on Tuesday, May 24, 2022 at 7:00 AM ET / 4:00 AM PT. The webcast of the presentation will be available on Silverback’s Investor Relations website for 30 days following the event. Members of the Silverback management team will also host investor meetings during the conference.
About Silverback Therapeutics
Silverback Therapeutics, Inc. is a biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. Silverback’s platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites. Silverback Therapeutics is located in Seattle, Washington. To learn more, visit www.silverbacktx.com.
When is Silverback Therapeutics presenting at the H.C. Wainwright Conference?
Silverback Therapeutics will present on May 24, 2022, at 7:00 AM ET.
What is the focus of Silverback Therapeutics?
Silverback Therapeutics focuses on developing therapeutics for chronic viral infections, cancer, and serious diseases using their ImmunoTAC technology.
Where can I watch Silverback's presentation from the conference?
The presentation will be available on Silverback's Investor Relations website for 30 days after the event.
What is ImmunoTAC technology?
ImmunoTAC technology is a proprietary platform that enables the development of tissue-targeted therapeutics by pairing payloads with monoclonal antibodies.
Who is the CEO of Silverback Therapeutics?
The CEO of Silverback Therapeutics is Laura Shawver, Ph.D.
